Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 63

Sort by

Sort Order Select

Journal Articles

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL

Georgios Pongas, Matthew Mei, Lu Chen, Geoffrey Shouse, Rachel Bellsmith, Ivana Melgar, Steven Rosen, Tanya Siddiqi, Alexey Danilov

Blood (2025) 146 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2025-2134

Published: 2025

Journal Articles

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Sairah Ahmed, Jinwen Cao, Matthew Mei, Amer Beitinjaneh, Helen Heslop, Maryam Alasfour, Mohamed Iburahim Haja Maideen, Omnia Farahat, Adam Braun, Peter Riedell, Natalie Grover, Carlos Ramos

Blood (2025) 146 (Supplement 1): 1844.

https://doi.org/10.1182/blood-2025-1844

Published: 2025

Journal Articles

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Ryan Lynch, David Russler-Germain, Joseph Schroers-Martin, Alison Moskowitz, Reid Merryman, Azra Borogovac, Hongyan Du, Heather Rasmussen, Ranjana Advani, Ash Alizadeh, Philippe Armand, Nancy Bartlett, Alex Herrera, Matthew Mei, Sarah Rutherford, David Kurtz, Ted Gooley, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5408.

https://doi.org/10.1182/blood-2025-5408

Published: 2025

Journal Articles

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

Blood (2025) 146 (Supplement 1): 3352.

https://doi.org/10.1182/blood-2025-3352

Published: 2025

Journal Articles

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Blood (2025) 146 (Supplement 1): 151.

https://doi.org/10.1182/blood-2025-151

Published: 2025

Journal Articles

Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy

Sairah Ahmed, Matthew Mei, Jinwen Cao, Amer Beitinjaneh, Helen Heslop, Maryam Alasfour, Omnia Farahat, Mohamed Iburahim Haja Maideen, Adam Braun, Daniel Reef, Peter Riedell, Natalie Grover, Carlos Ramos

Blood (2025) 146 (Supplement 1): 5938.

https://doi.org/10.1182/blood-2025-5938

Published: 2025

Journal Articles

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Blood (2025) 146 (Supplement 1): 6364.

https://doi.org/10.1182/blood-2025-6364

Published: 2025

Journal Articles

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

Monzr M. Al Malki, Susanta Hui, Dongyun Yang, Sally Mokhtari, Hoda Pourhassan, Matthew Mei, Amanda Blackmon, Firoozeh Sahebi, Amandeep Salhotra, Brian Ball, Shukaib Arslan, Salman Otoukesh, Haris Ali, Guido Marcucci, Ryotaro Nakamura, Stephen Forman, Anthony Selwyn Stein, Jeffrey Wong

Blood (2025) 146 (Supplement 1): 376.

https://doi.org/10.1182/blood-2025-376

Published: 2025

Journal Articles

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

Lindsey Murphy, Molly Thornock, Xinyi Du, Alysia Bosworth, Lanie Lindenfeld, Matthew Mei, Leslie Popplewell, Nicole Karras, Anna Pawlowska, Alex Herrera, F. Wong, Stephen Forman, Elizabeth Budde, Saro Armenian

Blood (2025) 146 (Supplement 1): 1013.

https://doi.org/10.1182/blood-2025-1013

Published: 2025

Journal Articles

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Blood (2024) 144 (Supplement 1): 3534.

https://doi.org/10.1182/blood-2024-207125

Published: 2024

Journal Articles

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

Tamer Othman, John H. Baird, Yan Wang, Stacy Pak, Ibrahim Aldoss, Ji-Lian Cai, Alexey Danilov, Tycel J. Phillips, Vaibhav Agrawal, Karamjeet S Sandhu, Matthew Mei, Paul B. Koller, Joycelynne Michelle Palmer, Stephen J. Forman, Lihua E. Budde, Ahmed Aribi

Blood (2024) 144 (Supplement 1): 2278.

https://doi.org/10.1182/blood-2024-207085

Published: 2024

Journal Articles

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

Maria Lia Palomba, Paolo F. Caimi, Matthew Mei, Francisco Hernandez-Ilizaliturri, Geoffrey Shouse, Allison M. Winter, Greg Yedinak, David Mou, Nestor Huang, Anna Moua, Martin Oft, Paul-Joseph Aspuria, Anita Mehta-Damani, Naiyer Rizvi, Sherry Unabia, Peg Taylor, Jeffrey McLeroy, Matthew J Cortese

Blood (2024) 144 (Supplement 1): 3453.

https://doi.org/10.1182/blood-2024-202090

Published: 2024

Journal Articles

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Blood (2024) 144 (Supplement 1): 652.

https://doi.org/10.1182/blood-2024-202153

Published: 2024

Journal Articles

Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation

June-Wha Rhee, Sitong Chen, Raju Pillai, Alysia Bosworth, Artem Oganesyan, Liezl Atencio, Caitlyn Estrada, Mareen Kassabian, Lanie Lindenfeld, Scott R. Goldsmith, Michael Rosenzweig, Alex F. Herrera, Matthew Mei, Ryotaro Nakamura, F. Lennie Wong, Stephen J. Forman, Saro Armenian

Blood (2024) 144 (Supplement 1): 947.

https://doi.org/10.1182/blood-2024-200402

Published: 2024

Journal Articles

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 1742.1.

https://doi.org/10.1182/blood-2024-198727

Published: 2024

Journal Articles

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

Joseph Maakaron, Dipenkumar Modi, Matthew Mei, Tatyana Feldman, Gunjan L. Shah, Amitkumar N. Mehta, Craig S. Sauter, Rashmi Khanal, Stefan K. Barta, Michael Emig, Lydia Wunderle, Andre Overesch, Alexandra Vasile, Jennifer Rubel, Thorsten Graef, Heather Raymon, Alison Moskowitz

Blood (2024) 144 (Supplement 1): 3052.

https://doi.org/10.1182/blood-2024-193896

Published: 2024

Journal Articles

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

Michael Wang, Patrick Connor Johnson, Salim Yazji, Yisrael Katz, Angela Pietrofeso, James Robinson, Matthew Mei, Matthew J. Frigault, James B. Breitmeyer, Caron A. Jacobson

Blood (2024) 144 (Supplement 1): 1743.

https://doi.org/10.1182/blood-2024-200998

Published: 2024

Journal Articles

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Blood (2024) 144 (Supplement 1): 459.

https://doi.org/10.1182/blood-2024-204113

Published: 2024

Journal Articles

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

Blood (2023) 142 (16): 1359–1370.

https://doi.org/10.1182/blood.2023020485

Published: 2023

Includes: Supplemental data

Journal Articles

The next frontier: enter PD-1 and exit PET scans?

Matthew Mei, Alex F. Herrera

Blood (2023) 141 (21): 2545–2546.

https://doi.org/10.1182/blood.2023020326

Published: 2023

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A phase 2 study with tafasitamab and zanubrutinib in newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma – taza CLL

Autologous CD30.CAR-T-cell therapy in patients with relapsed or refractory classical Hodgkin lymphoma – long term update of the chariot trial

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

High efficacy of blinatumomab combined with pembrolizumab in patients with relapsed/refractory (r/r) B cell acute lymphoblastic leukemia (B-ALL): primary analysis of a Phase 1/2 study

3-year follow-up of the S1826 study confirms improved progression-free survival with nivolumab-AVD compared to brentuximab vedotin-AVD in advanced stage classic Hodgkin lymphoma

Long term follow up autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy

High rates of financial toxicity and time toxicity in patients receiving chimeric antigen receptor therapy and bispecific antibodies for lymphoma and multiple myeloma: A prospective mixed methods study.

Total marrow and lymphoid irradiation (TMLI) with fludarabine-melphalan (FM) conditioning for matched donor hematopoietic cell transplant (HCT) in older patients with Relapsed/Refractory (R/R) disease

CAR T-cell therapy outcomes in adolescent and young adult patients with non-Hodgkin lymphoma

Impact of Prior Chimeric Antigen Receptor T-Cell Treatment on Graft-Vs-Host Disease and Non-Relapse Mortality after Allogeneic Hematopoietic Cell Transplantation: A Case-Control Propensity Matching Analysis

Outpatient Administration of Brexucabtagene Autoleucel (brexu-cel) for Acute Lymphoblastic Leukemia (ALL) and Mantle Cell Lymphoma (MCL) Is Safe and Feasible

A Phase 1 Study to Evaluate the Safety and Tolerability of a Combination Autologous CD19 CAR T Cell Therapy (SYNCAR-001) and Orthogonal IL-2 (STK-009) in Subjects with Relapsed or Refractory CD19 Expressing Hematologic Malignancies (NCT05665062)

The Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in 718 Patients with Large B Cell Lymphoma Receiving Polatuzumab Vedotin

Clonal Hematopoiesis Is Associated with Non-Myeloid Subsequent Malignant Neoplasms after Autologous Hematopoietic Cell Transplantation

A Phase 2 Study of Loncastuximab Tesirine Plus Mosunetuzumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Investigating the Novel Combination of the Innate Cell Engager (ICE®) Acimtamig with Off-the-Shelf Allogeneic Natural Killer Cells AlloNK® in Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL): Initial Results of the Phase 2 Luminice-203 Study

A Phase 1/2 Study of a ROR1-Targeting CAR T Cell Therapy (ONCT-808) in Adult Patients with Relapsed/Refractory (R/R) Aggressive B Cell Lymphomas (BCL)

A Randomized Phase 2 Study Incorporating Nivolumab and Brentuximab Vedotin into Radiation-Free Treatment of Early Stage Classic Hodgkin Lymphoma

Pembrolizumab plus vorinostat induces responses in patients with Hodgkin lymphoma refractory to prior PD-1 blockade

The next frontier: enter PD-1 and exit PET scans?

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only